Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24097872 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Diego Claro de Mello und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: São Paulo Research Foundation, National Council for Scientific and Technological Development, NapmiR.
Abstract (Originalsprache)
Anaplastic thyroid cancer (ATC) is a rare and lethal form of thyroid cancer that requires urgent investigation of new molecular targets involved in its aggressive biology. In this context, the overactivation of Polycomb Repressive Complex 2/EZH2, which induces chromatin compaction, is frequently observed in aggressive solid tumors, making the EZH2 methyltransferase a potential target for treatment. However, the deregulation of chromatin accessibility is yet not fully investigated in thyroid cancer. In this study, EZH2 expression was modulated by CRISPR/Cas9-mediated gene editing and pharmacologically inhibited with EZH2 inhibitor EPZ6438 alone or in combination with the MAPK inhibitor U0126. The results showed that CRISPR/Cas9-induced EZH2 gene editing reduced cell growth, migration and invasion in vitro and resulted in a 90% reduction in tumor growth when EZH2-edited cells were injected into an immunocompromised mouse model. Immunohistochemistry analysis of the tumors revealed reduced tumor cell proliferation and less recruitment of cancer-associated fibroblasts in the EZH2-edited tumors compared to the control tumors. Moreover, EZH2 inhibition induced thyroid-differentiation genes’ expression and mesenchymal-to-epithelial transition (MET) in ATC cells. Thus, this study shows that targeting EZH2 could be a promising neoadjuvant treatment for ATC, as it promotes antitumoral effects in vitro and in vivo and induces cell differentiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil.
ORCID-Profile: Diego Claro de Mello, Kelly Cristina Saito, Edna Teruko Kimura, Cesar Seigi Fuziwara
Förderung
- São Paulo Research Foundation
- National Council for Scientific and Technological Development
- NapmiR
- São Paulo Research Foundation—FAPESP
- National Council for Scientific and Technological Development—CNPq
Zitieren
APA
de Mello, D. C., Saito, K. C., Cristovão, M. M., Kimura, E. T., & Fuziwara, C. S. (2023). Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24097872
Vancouver
de Mello DC, Saito KC, Cristovão MM, Kimura ET, Fuziwara CS. Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24097872
BibTeX
@article{deMello2023,
author = {de Mello, Diego Claro and Saito, Kelly Cristina and Cristovão, Marcella Maringolo and Kimura, Edna Teruko and Fuziwara, Cesar Seigi},
title = {Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24097872}
}
EUVIMED